Blockchain Registration Transaction Record
NRx Pharmaceuticals Acquires Kadima Neuropsychiatry Institute for Interventional Psychiatry Treatments
NRx Pharmaceuticals announces acquisition of Kadima Neuropsychiatry Institute, expanding its portfolio of interventional psychiatry treatments for CNS disorders. Dr. David Feifel to join as Chief Medical Innovation Officer, signaling a strategic growth move in the biopharmaceutical industry.

This news matters because the acquisition of Kadima by NRx Pharmaceuticals signifies a strategic move to expand its offerings in treating CNS disorders. With Kadima's expertise in interventional psychiatry, NRx is positioning itself as a leader in providing innovative treatments for conditions such as suicidal depression and PTSD.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0xf2ea1e88dc670a4b8a5d04c1fbda6312057cd3b81726f6561107b2648b079d19 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | yogaV71b-412d9896cc6b19352945d5965d7fab2c |